Vaccine by Kochhar, Sonali et al.
Introduction of new vaccines for immunization in pregnancy – 
Programmatic, regulatory, safety and ethical considerations
Sonali Kochhara,b,c,*, Kathryn M. Edwardsd, Alba Maria Ropero Alvareze, Pedro L. Morof, 
Justin R. Ortizc,g
aGlobal Healthcare Consulting, New Delhi, India bDepartment of Public Health, Erasmus MC, 
University Medical Center, Rotterdam, the Netherlands cDepartment of Global Health, University 
of Washington, Seattle, USA dDivision of Infectious Diseases, Department of Pediatrics, 
Vanderbilt University Medical Center, TN, USA eComprehensive Family Immunization Unit, 
Department of Family, Health Promotion and Life Course (FPL). Pan American Health 
Organization (PAHO/WHO), Washington DC, USA fImmunization Safety Office, Division Of 
Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, USA gCenter 
for Vaccine Development and Global Health, University of Maryland School of Medicine, 
Baltimore, MD, USA
Abstract
Immunizing pregnant women is a promising strategy to reduce infectious disease-related 
morbidity and mortality in pregnant women and their infants. Important pre-requisites for the 
successful introduction of new vaccines for immunization in pregnancy include political 
commitment and adequate financial resources: trained, committed and sufficient numbers of 
healthcare workers to deliver the vaccines; close integration of immunization programs with 
antenatal care and Maternal and Child Health services; adequate access to antenatal care by 
pregnant women in the country (especially in low and middle-income countries (LMIC)); and a 
high proportion of births occurring in health facilities (to ensure maternal and neonatal follow-up 
can be done). The framework needed to advance a vaccine program from product licensure to 
successful country-level implementation includes establishing and organizing evidence for 
anticipated vaccine program impact, developing supportive policies, and translating policies into 
local action. International and national coordination efforts, proactive planning from conception to 
implementation of the programs (including country-level policy making, planning, and 
implementation, regulatory guidance, pharmacovigilance) and country-specific and cultural factors 
must be taken into account during the vaccines introduction.
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1. Introduction
Immunization in pregnancy is a promising strategy to reduce infectious disease-related 
morbidity and mortality in pregnant women and their infants [1,2]. Pregnant women and 
their infants are at high risk of adverse pregnancy outcomes from infections e.g. influenza in 
the last trimester can lead to severe maternal disease and rubella and zika infections in the 
mother can lead to congenital anomalies, such as congenital microcephaly. Approximately 
1.8 million children die within the first month of life [3] with many deaths due to infections 
with the potential to be prevented through existing vaccines or vaccines under development 
for delivery to pregnant women. Immunization in pregnancy protects the mother, the fetus 
and the newborn through the transplacental delivery of high concentrations of protective IgG 
(Immunoglobulin G) antibodies, particularly before active immunization of the infant can be 
initiated. There is also an indirect protective effect of the immunization by preventing 
infection in the mother, blocking subsequent transmission of infection to the infants 
(cocooning) [4].
Vaccines against tetanus, pertussis and seasonal influenza have been recommended for 
routine immunization in pregnant women in high-income countries (HIC) and in some low 
and middle-income countries (LMIC) for many years and have been determined to be safe 
and effective at preventing infections [1,2,5]. In spite of this, their uptake has been variable 
and for some of them e.g. influenza vaccine, well below desired levels. Despite a 
recommendation by WHO, influenza immunization for pregnant women has not been 
incorporated into immunization programs in many LMIC. Concerns about immunization of 
pregnant women include safety of the vaccine for the mother and fetus, vaccine effectiveness 
in disease prevention, limited data on the overall disease burden in pregnant women and 
their infants, and the lack of concern for disease by the health care provider and the mother. 
New vaccines for administration to pregnant women are currently under development such 
as respiratory syncytial virus (RSV), group B streptococcus (GBS), cytomegalovirus (CMV) 
[2,6,7] and monovalent pertussis vaccines [8].
In 2015, the World Health Organization (WHO) Strategic Advisory Group on Immunization 
(SAGE) reviewed progress toward implementation of maternal influenza immunization in 
pregnancy globally [9]. SAGE noted that there are still limited data from pregnant women, 
healthcare providers, and immunization program managers to inform implementation, 
communications, and advocacy, particularly in low resource settings.
2. Implementation of immunization in pregnancy
While awaiting the licensure of new maternal vaccines, generalizable data can and should be 
collected from existing maternal immunization programs regarding important pre-requisites 
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for their success. These include: political commitment and adequate financial resources; 
trained, committed and sufficient numbers of healthcare workers (HCW) to deliver the 
vaccines; close integration of antenatal care and existing maternal and child health and 
immunization programs, especially in LMIC; adequate access to antenatal care by pregnant 
women in the country; and a high number of pregnant women delivering in health facilities 
(so that maternal, neonate and infant follow-up can be adequately done) [10–13].
2.1. Framework for country-level implementation for a new vaccine for pregnant women
Based on the relatively recent adoption of Haemophilus influenzae type b (Hib), rotavirus 
and pneumococcal conjugate vaccines for infants in LMIC and on an existing set of WHO 
guidelines for new vaccine introduction [10], a group of vaccine authorities developed a 
theoretical framework for the supportive data, policies, and activities needed to advance a 
vaccine program from product licensure to successful country-level implementation (Fig. 1) 
[11]. This schematic organizes the major steps in the process of establishing and organizing 
evidence, developing supportive global policies, and translating policies into local action. 
International and national coordination efforts, proactive planning from conception to 
implementation and country-specific, cultural and local factors must be considered during 
the implementation of the immunization in pregnancy programs [11–13]. We will use this 
framework developed for implementation of infant immunizations to discuss the specific 
approach to immunization in pregnancy.
2.2. Supportive global vaccine policy
The WHO has recommended routine immunization of pregnant women with tetanus, 
pertussis, and influenza vaccines in certain contexts [14–16]. Other vaccines are 
recommended in pregnant women with high-risk exposure during outbreaks, including 
meningococcal and yellow fever vaccines [17,18]. WHO has also produced guidance for 
new vaccine introduction into routine immunization schedules [10], a global guidance 
document for maternal influenza immunization implementation, as well as a broader 
maternal immunization field guide for the Americas [19,13]. WHO antenatal care guidelines 
also recommend strengthening immunization platforms during pregnancy [20]. WHO’s 
Global Advisory Committee on Vaccine Safety has extensively reviewed and published on 
the safety of immunization during pregnancy. They found no evidence of adverse pregnancy 
outcomes from maternal immunization with inactivated virus or bacterial vaccines, or toxoid 
[21].
For LMIC eligible for financing by GAVI, financial support is an important prerequisite for 
new vaccine introduction. GAVI’s financing decisions are determined by their Vaccine 
Investment Strategy (VIS) recommendations, which are reviewed every 5 years. These 
recommendations are based on the vaccine’s impact on health, equity and social protection, 
value for money, economic impact and global health security. WHO works closely with 
GAVI to determine the new vaccines that will be included in the next VIS cycle and helps to 
develop the evaluation criteria based on potential cost, vaccine impact and implementation 
feasibility.
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2.3. Country level policy making
The Expanded Programme on Immunization (EPI) managers in countries make a 
preliminary, decision regarding the introduction of new vaccines or the expanded use of 
existing vaccines based on the political, financial, technical, programmatic, and feasibility 
considerations. The individual country National Immunization Technical Advisory Groups 
(NITAG) must support any decision [22]. Once there is a technical consensus, the proposal 
can be presented to the political decision-makers [14].
According to the Global Vaccine Action Plan, endorsed by the WHO Member States, every 
country has committed to having independent NITAGs. They assist their governments in 
immunization policy formation by providing evidence-based advice [22]. Small countries in 
close proximity, with similar epidemiologic profiles, and with other commonalities may 
participate in sub-regional immunization technical advisory groups e.g. Caribbean 
Immunization Technical Advisory Group (CITAG) (a sub-regional NITAG) for the 22 small 
countries/territories in the Caribbean [23].
Each NITAG interprets available data to determine the policy recommendations that make 
the most sense within the national context. Some of the evidence that may be reviewed by 
the NITAGs for the introduction of vaccines for pregnant women is listed in Table 1 [14,24]. 
Existence of these data would help to assess whether the introduction of the vaccines for 
pregnant women into the national immunization program would achieve the desired national 
public health objectives.
Guidance for the introduction of immunization in pregnancy programs is also available from 
national public health agencies and medical societies like the American College of 
Obstetricians and Gynecologists [25].
2.4. Planning and implementation
After the decision to introduce a vaccine, a plan of action for the introduction of the new 
vaccines for pregnant women should be developed. Some suggested points for consideration 
are included in Table 2 [13,14].
3. Vaccine offered to pregnant women
The vaccine could be offered to the pregnant women as part of antenatal care (ANC) visits 
(along with other health interventions routinely offered in the country), outpatient care (as 
part of general practice, gynecology, or high-risk clinics), vaccination on demand and at 
other health services that pregnant women might seek for their own care or for the care of 
their other children. Strengthening existing maternal and neonatal initiatives such as 
prevention of mother to child transmission of HIV or syphilis and incorporating 
immunization of pregnant women into these initiatives would be useful. Outreach strategies 
could include house-to-house vaccination, vaccination campaigns, vaccinating pregnant 
women at work and educational facilities, and mobile vaccination clinics.
The timing of immunization is important, especially in LMIC where pregnant women often 
access ANC initially in their second or third trimesters. This also avoids concerns of effects 
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on fetal development or association mistakenly with fetal loss (which is common in the first 
trimester). Placental transport is most effective from approximately 34 weeks of gestation 
and higher levels of maternal antibodies are available for transportation to the fetus, resulting 
in optimal protection of the newborn infant. The first dose of the routine immunization is 
started early in the neonatal period in LMIC, hence the transplacental antibodies are required 
to persist for a relatively short duration to protect the infant. For example, for Tetanus 
Toxoid (TT) vaccines in India, if the immunization status of the pregnant woman is 
unknown, the recommendation is immunization as soon as the pregnancy is detected 
followed by a second dose after 4 weeks. If the woman received two doses of TT in her 
previous pregnancy within 3 years, then one dose of TT is recommended 4 weeks prior to 
the expected date of delivery.
Vaccination coverage in pregnant women could be used as an indicator for the integration of 
immunization in pregnancy with ANC services. Latin American countries have successfully 
implemented these health policies [14,26].
4. Advantages of immunisation in pregnancy programs integration with 
antenatal care services
Immunization in pregnancy could provide additional benefits beyond the prevention of 
infectious diseases in the mother and infant. Health systems for antenatal care delivery, in 
general, could benefit from efforts to strengthen vaccine delivery, with increased attention to 
evidence-based policy-making, regulation, staffing, training, documentation, cold chain, 
supply chain, monitoring and evaluation of coverage, adverse event assessment, and quality 
of care metrics [27]. It would potentially improve coverage, reduce costs, and increase the 
efficiency of both the antenatal care and immunization programs [14]. Pregnant women and 
their families can also benefit if vaccine introduction encourages increased antenatal care 
attendance, counselling, and recommended screening and interventions during pregnancy 
[28,29]. Systemic factors that are important to improve ANC utilization in LMIC include the 
quality and satisfaction associated with the service. Provision of immunization might help to 
improve both these factors and encourage ANC uptake. Further, accompanying family 
members could also receive catch-up immunization or care during these interactions if the 
services for them were available at the health centers [30]. This would decrease the time that 
families must invest in traveling to health facilities and the economic costs to the families 
and society. However, for these integrated efforts to be successful, health system 
strengthening is critical. This is currently often not the case in some HIC and LMIC, 
especially in smaller health care clinics in these countries, as there currently are different 
days for ANC and childhood immunizations.
5. Challenges for immunisation in pregnancy implementation
While safe and effective vaccines and global policies recommending their use are necessary 
for the success of a new vaccine program, they are not sufficient. Nowhere is this 
observation more relevant than with the maternal influenza immunization strategy. Influenza 
vaccines have an excellent safety profile in pregnant women [31], have been shown to 
prevent maternal influenza [32], and have been documented to confer protection against 
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influenza in infants [33]. However, although pregnant women are recommended to be 
prioritized for influenza vaccine receipt by the WHO, only 42 percent of WHO Member 
States have adopted recommendations for immunization of pregnant women with influenza 
vaccines, mostly in the American Region [34]. The coverage of influenza immunization of 
pregnant women in the United States is less than 50 percent despite recommendations for 
many years from the Centers for Disease Control and Prevention (CDC), Advisory 
Committee on Immunization Practices (ACIP) and the American College of Obstetricians 
and Gynecologists (ACOG) [25]. Maternal influenza immunization has not been adopted by 
most LMIC. Reasons for not having a national maternal influenza vaccination policy are 
multifactorial and differ among countries. Countries with policies tend to be HIC, use more 
new vaccines, have more robust NITAGs to formulate vaccine policy recommendations, and 
have stronger health systems to administer vaccines [34].
In the case of maternal influenza immunization, key data gaps and challenges remain. Expert 
reviews of the strategy have identified lack of robust estimates for severe influenza disease in 
mothers or their infants as a major obstacle to the strategy [33,35]. Effective mechanisms for 
the purchase and procurement of influenza vaccines are also critical for successful 
immunization programs [36].
To implement an immunization in pregnancy program for a new vaccine, programmatic 
challenges exist in using the antenatal care platform to immunize pregnant women. The 
capacity of antenatal care to deliver vaccines is LMIC is poorly characterized, however in 
these settings antenatal care is likely to be in need of strengthening. WHO has recommended 
that pregnant women should have at least 8 antenatal visits [37] and has highlighted the need 
to improve the quality and monitoring of antenatal care. Only about 42 percent of women 
from LMIC have at least four antenatal care visits, and 35 percent still only have one 
antenatal care visit [38,39]. Robust antenatal care involves the delivery of many evidence-
based interventions across several visits [40]. A review of the quality of antenatal care found 
the coverage of important evidence-based interventions to be suboptimal in many LMIC 
[41].
Some of the factors which add further to the complexity of the introduction of new vaccines 
for pregnant women are mentioned in Table 2 [42,43,2,14]. Integrated approaches would 
need to be supported by the availability of adequate numbers and trained HCW, financial 
resources, logistics of vaccine acquisition, storage, administration, and tracking, and 
consistent tools and documents across different programs and services [44]. It is unknown 
how integrated service delivery can affect the smooth operations of health care delivery. On 
the one hand, it may decrease the time and the economic costs to the families and society, 
but on the other hand, it may possibly increase HCW’s daily burden of work and may 
require additional training, resources and support. Some of the barriers that affect HCW 
provision of vaccines during pregnancy and measures to address the issues are listed in Table 
3 [1,14,45–47].
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6. Vaccine hesitancy
Vaccine hesitancy is the refusal of vaccines or a delay in acceptance despite the availability 
of immunization services. It is often cited as a problem that can be particularly acute during 
pregnancy, as pregnant women are encouraged to avoid medicines with known or uncertain 
risks to the fetus. Some of the factors influencing vaccine hesitancy and the measures to 
address it in pregnant women, their partners, and extended families are mentioned in Table 4 
[1,14,43,46–48].
Lower uptake of vaccination in pregnancy has been associated with younger age, not being 
married, lacking healthcare insurance or an obstetric care provider, having a history of pre-
term delivery, belonging to a lower socioeconomic status, having a lower educational level, 
and being a racial or ethnic minority [1,14,43,46–48].
To address this issue, communication, advocacy, and social mobilization are useful to 
increase awareness among key stake-holders about the importance of immunization of 
pregnant women, adhering to the vaccination schedule, the safety and effectiveness of the 
vaccines, avoiding miscommunication and rumors, improving immunization coverage and 
rapid detection, reporting and addressing of possible adverse events (AE) following 
immunizations (AEFIs). Research from HIC and LMIC has shown that understanding the 
benefits of immunization by pregnant women (and especially in LMIC, their partners, and 
extended families) comes through education by HCW, and high-quality obstetric care with 
acceptable and affordable immunization services offered through well-staffed clinics, 
pharmacies, churches, and other settings. Recent studies support the development of 
interventions to promote vaccine uptake which are evidence-based and highlight vaccine 
safety during pregnancy to reduce these concerns [2,49].
7. System considerations
7.1. International regulatory guidance
National Regulatory Authorities in LMIC often refer to international guidelines from the 
Food and Drug Administration (FDA) and European Medicines Agency (EMA). Available 
guidance from the FDA and EMA and International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) highlight 
a lack of harmonization and safety monitoring expectations for immunization in pregnancy 
[2,50]. These vaccines present significant regulatory challenges because their safety and 
efficacy must be determined both in the mother and infant. In the ICH and FDA guidelines, 
general guidance is available and specific requirements are now emerging, with the inclusion 
of available data in the vaccine label on immunization of pregnant women [2,51].
In the United States, no vaccine currently has an approved label for an indication for use 
during pregnancy. This is due to a lack of evidence from controlled clinical trials in pregnant 
women at the time of initial licensure of the vaccine, on the safety of the vaccine in the 
vaccinated woman and infant and the effectiveness of the vaccine to protect the infant. This 
is needed to include an indication for use in pregnant women in the vaccine label. Pregnant 
women were excluded from most pre-licensure trials for licensed vaccines in HIC. Public 
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health authorities have recommended the same vaccine for immunization in pregnancy based 
on reproductive toxicity studies in the preclinical phase, post-licensure surveillance, 
observational studies, data from small numbers of pregnant women inadvertently vaccinated 
in vaccination campaigns and clinical trials, and the vaccine’s perceived benefit and minimal 
risk for the mother and infant [2,51,52]. Currently, vaccines recommended by the ACIP (e.g. 
Tetanus, Diphtheria and Pertussis (Tdap), and inactivated influenza) can be used in pregnant 
women, as they are approved for use in adults and not contraindicated for use during 
pregnancy [2,51–53].
Differences between the public health recommendations regarding the vaccine use in 
pregnant women and the absence of the indication on the vaccine label can lead to confusion 
in HCW and pregnant women and result in lower compliance with national vaccination 
recommendations [54]. The language in the vaccine inserts may be misinterpreted to suggest 
safety concerns [2,51,53]. To address the potential for misinterpretation of -pregnancy-
related language in vaccine inserts, the FDA issued the Pregnancy and Lactation Labeling 
Rule (PLLR) to improve understanding of vaccine risks [2,50,52,55]. The PLLR eliminates 
the earlier letter categories (A, B, C, D, X) meant to signify risk, which were difficult to 
practically implement [2,54].
The revised PLLR regulation requires narrative descriptions of clinically relevant 
information on the risks of using the vaccine in pregnant and lactating women to be included 
in the label. The data can come from clinical trials, epidemiologic studies, pregnancy 
registries, and case series reporting rare events. As new information becomes available, the 
vaccine label needs to be updated. This may help towards informing HCW’s prescriptions 
for immunization, counselling pregnant women and communicating information on the 
benefits and risks of the vaccine use in pregnancy and lactation and in males and females 
with reproductive potential [2,52,55,56].
In 2015, the Vaccines and Related Biological Products Advisory Committee of the FDA 
determined that the regulatory approval process for vaccines for use in pregnant women to 
prevent disease in the infant will be guided by regulations in Title 21 of the Code of Federal 
Regulations (21 CFR) and standards mentioned in applicable guidance documents i.e. the 
ICH and FDA Guidance documents. The vaccine development program and licensure will be 
product-specific to support the particular indication. Key considerations could include the 
use of immunological endpoints as markers of infant protection, evaluation of immune 
interference of transplacentally derived antibody with childhood vaccines and the duration of 
immunity in both the vaccinated woman and infant. Observational studies could be used for 
the study of licensed vaccines already recommended for use during pregnancy [2,54].
Using standardized case definitions for maternal and neonatal outcomes will enable the 
pooling of data from clinical and observational studies for the vaccine labels [2]. Having 
clarity regarding vaccine labeling related to pregnancy will help reduce variability in the 
labels and ensure that health care providers and pregnant women have a higher level of 
confidence in vaccines to be administered in pregnancy. This will hopefully increase the 
uptake of immunization in pregnancy [2,52,53]. Well-defined international guidance could 
provide a roadmap for regulation of vaccines used during pregnancy in LMIC.
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For new RSV and GBS vaccines under development, advance agreement on the design and 
parameters of clinical trials that could support licensure for immunization in pregnancy by 
regulatory authorities in countries will be useful. Important work done by WHO to define 
the technological roadmap and preferred product characteristics for the RSV and GBS 
vaccines has been accomplished [57,58]. Another area of importance will be to agree on 
plans regarding post-licensure (either full or conditional licensure) follow-up to gather 
further safety and efficacy information from the field if investigational candidate vaccines 
are deployed in LMIC that currently do not have systems for such surveillance in place.
7.2. Pharmacovigilance of immunisation in pregnancy
Monitoring the safety of vaccines in the woman and infant should be an important part of 
any immunization in pregnancy program. HIC have developed vaccine safety monitoring 
systems that have been used to monitor the safety of vaccines for pregnant women [59–63]. 
Unlike HIC, LMIC face challenges in their efforts to monitor the safety of immunization in 
pregnancy. Some limitations encountered by LMIC include lack of background population 
data on important pregnancy or infant outcomes necessary for immunization in pregnancy 
safety surveillance [2,64]. Prematurity, small for gestational age, and pregnancy 
complications are not uncommon in pregnancies, even in the absence of vaccination. The 
baseline rates of adverse pregnancy outcomes in a population should be enumerated to 
understand expected baselines of AE to inform vaccine safety assessments and clinically 
important effect sizes, if there were safety signals that must be captured by safety 
monitoring systems [2,65].
Adverse events following immunization (AEFI) surveillance should be established to 
identify AE if they were to occur. This is to ensure that the risk–benefit balance remains 
positive in pregnant women and their newborns [66]. Vaccine pharmacovigilance includes 
three stages: signal detection, development of a causality hypothesis, and testing of the 
hypothesis [67].
7.2.1. Spontaneous reporting systems—Signal detection in the post-marketing 
setting mainly relies on spontaneous reports of AEFI and literature case reports (passive 
pharmacovigilance) [67].
Many LMIC have spontaneous reporting systems with different degrees of 
pharmacovigilance [68]. There are national spontaneous reporting databases that collaborate 
with the WHO Programme for International Drug Monitoring. The Global Individual Case 
Safety Reports Database System (VigiBase) is a WHO global database which contains over 
16 million individual case safety reports with member countries of the WHO Programme for 
International Drug Monitoring submitting reports since 1968. VigiBase is linked to medical 
and drug classifications such as WHO ART (Adverse Reactions Terminology), MedDRA 
(Medical Dictionary for Regulatory Activities), WHO ICD (International Classification of 
Diseases), and WHODrug to enable structured data entry, retrieval and analysis [69]. 
Analyses of spontaneous reports may provide a signal for higher than expected AE rates or 
potentially previously unrecognized AE. However, there are many limitations to the 
evaluation of passive reports including extremely low reporting of AEFIs by healthcare 
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providers [2,66], selective reporting of AE, lack of denominator data, incomplete data on 
AE, lack of evidence supporting the diagnosis submitted in many reports and the lack of 
control groups [70].
AEFI causal relationships can usually not be determined based on individual reports [71]. 
Determining if there is a causal relationship between vaccination in early pregnancy and 
birth defects would require a statistically significant difference in the group of pregnant 
women receiving the vaccines compared to a control group. This is often limited by an 
inadequate sample size/power to detect differences. A false positive finding, where an 
association between the vaccine and outcome is incorrectly identified can potentially affect 
public trust in vaccination and/or the rates of vaccine coverage [2,72,73].
7.2.2. Active surveillance—Signals coming from spontaneous reports warrant 
additional epidemiological and clinical investigations and further confirmation in a 
controlled study may be required [73]. Pharmacoepidemiological studies using large 
electronic health record databases make it possible to study the association of rare AE and 
provide timely answers to meet the short deadlines of the pharmacovigilance decision-
making process. This not only simplifies the logistics and reduces the costs of 
pharmacoepidemiological research, but can also increase it validity [74]. However, these 
electronic databases contain observational data which has not been collected for research 
purposes. Vaccine safety studies that use these databases are limited by the quality of the 
information. As a result, biased results due to potential misclassification of the exposure 
(vaccination) and/or outcome (AE) are possible [75]. The combined use of multiple 
healthcare databases for the conduct of post-marketing active surveillance studies for 
vaccine safety is being increasingly done especially in HIC to increase the statistical sample 
size and heterogeneity of exposure. There are issues associated with this approach, including 
the different underlying healthcare systems, type of information collected, lack of 
harmonized case definitions, medical event coding systems, language and programs selected 
for data management and analyses. These large databases also need to respect country-
specific data anonymization and privacy regulations. Specific software (e.g. Jerboa) deal 
with privacy issues by using a common data model and sharing only aggregated and 
anonymized data. Providing remote research environments for storage and safe access to the 
data from different databases is necessary [76].
Several HIC have developed active surveillance systems for AEFI for analyses of the 
association between a vaccine and one or more pre-specified adverse health outcomes e.g. 
CDC’s Vaccine Safety Datalink (VSD), the US FDA’s Post-Licensure Rapid Immunization 
Safety Monitoring (PRISM) and IMPACT, Canada’s Immunization Monitoring program. 
Rapid Cycle Analysis (RCA) (frequent (e.g., weekly) analysis) of the VSD allows more 
timely analysis of pre-specified AE of special interest so the general public can be informed 
rapidly of possible risks of recently licensed vaccines or new immunization schedules. 
TreeScan (https://www.treescan.org/), a free analytical software for large datasets, can be 
used to identify previously unspecified outcomes by simultaneously evaluating thousands of 
groups of AE and potential AE, to determine if there is a higher probability of any adverse 
event occurring among people exposed to a particular vaccine [77].
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Some LMIC have surveillance and survey systems in place that have been established to 
collect population health data including maternal health data e.g. health and demographic 
surveillance systems (HDSS). However, such databases might contain aggregated data 
making analysis impossible at the individual level. Households are visited regularly and this 
could serve as a platform to collect data on the safety of immunization in pregnancy. 
Pregnancy registries may be set up and used to collect immunization in pregnancy safety 
data, but their use in LMIC has been limited. Health information systems (HIS) can collect 
data on subjects who attend health facilities; however, they can lack standardized definitions 
and be biased. One potential approach for safety monitoring of maternal vaccines in LMIC 
is the use of a network of hospitals or health centers within a country or in several countries 
using case-only analytic methods to circumvent the difficulty of obtaining denominator data 
to calculate rates of AE. An example of this is monitoring conducted by the Pediatric 
Investigators Collaborative Network on Infections (PICNIC) in Canada for RSV-associated 
deaths in pediatric patients [78]. A similar approach could be used to study the safety of 
vaccines for pregnant women as was done to assess the safety of the pandemic H1N1 
influenza vaccine in pregnant women in Taiwan [79]. Landscape analysis could be used to 
identify sentinel surveillance sites in countries to study the safety of vaccines administered 
to pregnant women.
The Latin American Center for Perinatology (CLAP) was established in 1970 with the aim 
of strengthening health care services especially primary care for mothers and neonates. In 
recent years, CLAP has compiled data from 29 countries in Latin America using an 
electronic, standardized perinatology clinical record. This tool has helped with the analyses 
of health outcomes of interest for Maternal and Neonatal Immunisation. CLAP is also 
establishing a surveillance network of sentinel hospital sites across the Region. These 
sentinel centers will actively look for and investigate pregnancy and infant outcomes 
following immunization in pregnancy [80].
A limitation, not unique to LMIC but also present in some HIC, is the lack of harmonized 
methods for vaccine safety studies, lack of standard definitions for important pregnancy and 
infant outcomes such as fetal loss, stillbirth, birth defects, and maternal morbidity and 
causality assessment for maternal or fetal AEFI in pregnancy [2,64,81]. This is being 
addressed through the Global Alignment of Immunization safety Assessment in pregnancy 
(GAIA) project, which was set up in 2014 in response to the WHO call for a globally 
concerted approach to actively monitor the safety of vaccines and immunization in 
pregnancy programs, with a specific focus on LMIC needs and requirements [2,64]. The 
project has developed a core set of 25 globally standardized case definitions of selected key 
obstetric and neonatal outcomes to determine the level of diagnostic certainty in the 
assessment of an event to ensure comparability and harmonization of data collected in 
different resource settings [81,82]. In addition, guidelines and tools for assessment of the 
safety of vaccines used in clinical trials in pregnant women have been developed. The 
guidelines have been supported by WHO Global Advisory Committee on Vaccine Safety 
[2,64,82,83]. The GAIA outputs have been developed based on a standard global consensus 
process with investigators, academia, vaccine manufacturers and public health institutes. 
They are being increasingly utilized in the field of immunization in pregnancy and maternal 
and child health [2,64].
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The surveillance of vaccine safety in pregnant women in LMIC is especially challenging. 
The small differences in risk that would be expected need big sample sizes to perform 
studies with adequate statistical power. To date, most published studies on vaccine safety in 
pregnancy have been from HIC [68]. This may be explained in part by the lack of 
appropriate databases in LMIC. The strengthening, adaptation, and use of the expanding 
information sources are the next step to generate complementary information for the 
continuous benefit-risk assessment process.
7.3. Ethical considerations for immunization in pregnancy programs
The principle of fair distribution of research benefits requires that research addresses diverse 
health needs across different classes/groups of people and not disproportionately focus on 
the health needs of a limited class of people. In the past, groups considered vulnerable have 
had additional protections to participate in research, often including investigations designed 
to exclude them (e.g. women of reproductive age, pregnant women, children etc.) [84–86]. 
Due to the exclusions, information about the prevention, diagnosis, and treatment of diseases 
that affect such groups is limited. This has resulted in injustice to pregnant women from a 
justice, equity, medical need, ethical and public health perspective [2,84–87]. Pregnant 
women were denied autonomy and a right to decide on research participation for themselves.
83Not vaccinating pregnant women deprives them of the protection they deserve against 
infectious diseases [84–87]. The International Ethical Guidelines for Health-related 
Research Involving Humans by the Council for International Organizations of Medical 
Sciences (CIOMS), in collaboration with WHO, note that pregnant women are not 
vulnerable simply because they are pregnant [84]. There is a need to redress these injustices 
by encouraging the participation of previously excluded groups, including pregnant women, 
in medical research and offering immunization to pregnant women if the vaccines have been 
licensed or recommended for use in pregnancy in those countries [2,84–87].
Based on the principle of autonomy, in no case must the permission of another person 
replace the requirement of individual informed consent by the pregnant woman to receive 
the vaccine. In case the pregnant women so desires, the information about the vaccines can 
be shared with her spouse and extended family [85,86]. Providing easily understandable, 
culturally sensitive, comprehensive information in the locally spoken language on the 
benefits and risks of immunization in pregnancy is important, so that pregnant women can 
make their own decision to get immunized [2,84–87].
Active dialogue between pregnant women and HCW in the community is necessary to 
understand pregnant women’s beliefs about the necessity and safety of immunization in 
pregnancy. Taking the perspectives of women seriously contributes to the ethical justification 
and trustworthiness of the program. Women should also be adequately represented in 
decision-making bodies that influence national- and international-level policy decisions 
about immunization in pregnancy programs (including the NITAG, community advisory 
groups, policymakers, scientific bodies’ etc.) [2,84–87].
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8. Advancing of immunisation of pregnant women
Robust disease burden and cost-effectiveness estimates for RSV and GBS are being 
collected and will serve to inform expectations of vaccine program impact [6,7]. These 
vaccines are also being developed with WHO programmatic suitability criteria in mind, so 
clinical development will consider issues of product storage volume, cold chain, injection 
devices, and waste disposal that are of particular concern in LMIC [88]. GBS and RSV 
vaccines have several advantages over influenza vaccines, as they will not require annual 
reformulation; they will likely have longer shelf lives, and will not require frequent stock 
rotations [6,7]. However, the kinetics of the antibody responses to these vaccines will need 
to be characterized [6,7]. Maternal antibodies generally wane over a period of less than 6 
months. If there are higher titers of maternal antibody present in the neonate after birth, they 
will persist for a longer time in the infant. Immunizing pregnant women during the late 
second or third trimester (after 20 weeks and, preferably at 27–36 weeks of gestation) is 
recommended [89,90].
There is reason to be optimistic about the implementation of immunization in pregnancy for 
a number of maternal and neonatal pathogens. Using GBS as an example, it will be far easier 
to administer a vaccine than to culture clinical specimens from every pregnant woman for 
GBS carriage and then treat each colonized women with antibiotics to prevent a single case 
of early-onset GBS disease [91]. Routinely collecting clinical specimens for culture from 
pregnant women for GBS is not done in LMIC. Even with the development of highly 
specific and sensitive rapid bedside GBS diagnostic tests, their use would likely not be 
possible in LMIC due to logistic and financial considerations. In addition, the culturing and 
treatment approach has no effect on the prevention of late-onset GBS meningitis in the 
infant, as shown by the existing data from the United States [92].
9. Conclusion
An investment in an immunization in pregnancy strategy would provide public health benefit 
by preventing infectious diseases in pregnant women and their infants and strengthening 
country antenatal care and health care delivery systems. To implement an immunization in 
pregnancy program for a new vaccine, programmatic challenges exist in using the antenatal 
care platform to deliver vaccines, especially in LMIC. These are mentioned in Table 2. 
Based on the lessons learned from current immunization in pregnancy programs, if the 
introduction of new vaccines for pregnant women is systemically done this may 
considerably decrease the morbidity and mortality associated with vaccine-preventable 
infectious diseases in pregnant women and their infants.
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Fig. 1. 
Schematic describing the evidence, policies, and actions required to achieve the successful 
implementation of a new vaccine strategy. Note: Adapted from a previously published work 
[12].
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Table 1
Some evidence needed by the National Immunization Technical Advisory Group (NITAG) for the introduction 
of Immunization in Pregnancy vaccines.
• Disease Burden
• Epidemiology
• Vaccine Safety
• Efficacy
• Effectiveness
• Cost-effectiveness
• Quality
• Anticipated impact of the immunization program
• Vaccines risk vs benefit for each target population
• Feasibility and scheduling (how the vaccine would fit into the national immunization schedule)
• Comparison of the impact of the vaccine with other interventions
• Demand forecast for the vaccine
• Regular and timely vaccine supply to meet the demand forecast
• Disease’s visibility in society and how it compares to other public health concerns
• Implementation costs of the new vaccine for pregnant women
• Current immunization program’s performance (to identify areas that need to be strengthened)
• Adequate infrastructure needed to monitor the disease burden and vaccine safety (maternal, fetal and infant adverse events)
• Regulatory and ethical considerations
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Table 3
Some barriers that impact Healthcare Workers (HCW) provision of vaccines during pregnancy and measures 
to address them.
Barriers
• Lack of knowledge and education
• Misconceptions about the risk of the disease
• Concerns about the need for vaccination during pregnancy and vaccine safety and efficacy
• Lack of training on the technical and communication aspects
• Vaccination not being part of their routine practice
• Misconceptions regarding their patients preference for vaccination doing pregnancy
• Lack of time, staff, vaccines, syringes, needles, cold chain equipment
• Increased workload
• Inadequate reimbursement
• Concern about liability
• Inconsistent guidelines
• Inability to track vaccination status of pregnant women
Measures to address the barriers
• Chart reminders
• Documentation in pregnancy records
• Medical notes and perinatal guidelines
• Education tailored to the needs of physicians (including family physicians and obstetricians),
HCW and Pregnant Women (including peer to peer training/ mentoring)
• Comprehensive guidelines
• Computer decision supporting algorithms that aid in identifying women needing immunization
• Standing and opt-in orders for vaccination
• Addressing liability issues
• Avoiding the administration of vaccines during the first trimester
• Information technology support for timely monitoring of program successes, challenges and impact of adding Immunisation in 
Pregnancy to the existing Programs
• Single-dose vaccination schedules
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